Live Granules India Share Price Chart

O 474.4

H 474.4

L 474.4

VOL 1987

Granules India Performance

Days Range

Low: ₹470.75
High: ₹476.80
Previous Close ₹474.40
Open ₹474.40
Volume 6,90,042
Day’s Range ₹470.75 - ₹476.80
52W Range ₹279.95 - ₹485.95
Market Cap ₹11,433 Cr

Granules India Fundamentals

ROCE (TTM) 14.38
P/E Ratio (TTM) 28.21
P/B Ratio 3.54
Industry P/E 35.51
Debt to Equity 0.41
ROE 12.57
EPS (TTM) 16.72
Dividend Yield 0.32
Book Value 133.08
Face Value 1

Granules India Financials

Jun 2023Sep 2023Dec 2023Mar 2024
Net Sales985.521,189.491,155.581,175.78
Profit before tax65.47136.02170.1175.64
Operating Profit47.9102.12125.65129.65
Net Profit47.9102.12125.65129.65
EPS in Rs1.984.225.185.35

About Granules India


Granules India Limited was founded on March 18th, 1991. It commenced its operations as a merchant exporter of bulk drugs like paracetamol, guaifenesin and chloropheniramine maleate. Since 1992, GIL concentrated on the export of paracetamol powder. In 1993, Granules established its first PFI facility at Jeedimetla. In 1995, Granules became a listed company, after having initial public offerings at the Hyderabad Stock Exchange.

In 2001, Triton Laboratories merged with Granules. Two years later, the company set up a new large-volume PFI facility in Gagillapur and a wholly owned subsidiary – Granules USA for marketing in the US. In 2005, A new Paracetamol plant was built in Bonthapally, Hyderabad. In 2008, Granules entered into the Finished Dosage segment. Granules received US FDA approval for its first Abbreviated New Drug Application (ANDA) in 2020.

In 2013, the company established an API R&D facility in Pragathi Nagar, Hyderabad further to strengthen its vision of being an integrated player. It entered the Over-the-Counter business in the US in 2015, through its own label Granules Consumer Healthcare for OTC products to control the value chain. Next year, Granules laid down the foundation for its Oncology OSD Plant in Visakhapatnam.

In 2016, Granules launched the Self Directed Team (SDT) program in manufacturing units to nurture skill development. In 2020, Granules laid the foundation for the largest single manufacturing site for the multi-unit pellet system facility, which was completed in 2022. The company launched a new greenfield packaging facility in Virginia, USA in 2022-23. The company established Granules CZRO, a wholly-owned subsidiary of Granules India Limited in 2023.

Over the years, the company has created a leadership position in the off-patent drugs segment, while ensuring a strong presence in certain first line of defence products, such as Paracetamol, Ibuprofen, Metformin and Guaifenesin. The company has a global presence across over 80 countries, servicing over 300 clients. In FY 2022-23, approximately 20% of the total energy consumed at the Formulation unit located at Gagillapur, Hyderabad was from Solar Energy.

Business Segments

  1. Active Pharmaceutical Ingredient (API)

Granules is a manufacturer of APIs, i.e. biologically active ingredients used for medical solutions. It operates manufacturing facilities with DCS (Distributed Control systems) to ensure minimal human intervention while maximising productivity and quality. It is a global leader in the production of Paracetamol, Metformin, Guaifenesin, and Methocarbamol.

  1. Pharmaceutical Formulation Intermediate (PFI)

PFIs are a blend of active and inert ingredients. Granules India pioneered the concept of commercialising PFIs or Pre formulation Intermediates, in order to reduce the cost of products. It is the largest PFI producer in India.

  1. Finished Dosage (FD)

The company is also an integrated manufacturer of Rx and OTC products, including multi-particulate pellet system-based products. It develops and manufactures tablets, capsules, press fits, oral solutions, suspensions and powder for oral solutions. It exports these, with a focus on North America, Europe and South Africa amongst others.


It has the following subsidiary companies, all of which are wholly owned subsidiaries:

  1. Granules USA, Inc.
  2. Granules Pharmaceuticals, Inc.
  3. Granules Europe Limited
  4. Granules Consumer Health
  5. Granules Life Sciences Private Limited
  6. Granules CZRO Private Limited

Of these, Granules Consumer Health is a wholly owned step down subsidiary.

Key Personnel

Dr. Krishna Prasad Chigurupati, Chairman and MD

Dr. Chigurupati’s pharmaceutical journey started in 1984 with the manufacturing of high-quality Paracetamol for global markets. He pioneered many innovations in pharmaceutical manufacturing, such as commercialising Pharmaceutical Formulation Intermediates as a cost-effective input for global finished dosage manufacturers. To date, he has filed 33 patents, out of which 5 patents have been granted so far. He expanded the company by setting up facilities across the continents in countries such as China and the US.

Corporate Actions

The company conducted the following corporate actions:

Buyback of Shares

The company conducted buyback of shares, once with a record date of August 23, 2022, and then with a record date of March 20, 2020.

Stock Split

Granules has split its stock once with a record date of March 24, 2015, from a face value of ₹10 to ₹1 per share.

Mergers and Acquisitions

  • In 2014, Granules acquired Auctus Pharma, an API manufacturing facility with regulatory approvals.
Parent Organisation Indian Private
Founded 1991
Managing Director C Krishna Prasad

Peer Comparison

Stocks Market Cap (cr) Market Price (₹) 52 Week Low-High (₹)
Supriya Lifescience Ltd ₹3,063.18


0.00 (0.00)

375 - 388.8View Peer Comparison
Celestial Biolabs Ltd ₹4.56


0.00 (0.00)

1.75 - 1.8View Peer Comparison
JFL Life Sciences Ltd ₹44.16


0.00 (0.00)

40.15 - 40.15View Peer Comparison
Procter & Gamble Health Ltd ₹8,221.90


33.85 (-0.68%)

4950 - 5021.3View Peer Comparison
Veerhealth Care Ltd ₹42.22


0.00 (0.00)

26 - 26View Peer Comparison

What's Trending

Granules India FAQs

What is the Share price of Granules India (GRANULES)?

Granules India (GRANULES) share price as of June 12, 2024, on NSE is Rs 472.10 (NSE) and Rs 481.00 (BSE) on BSE.

Can I buy Granules India (GRANULES) shares?

Yes, You can buy Granules India (GRANULES) shares by opening a Demat account with Angel One.

How do I buy Granules India (GRANULES) from Angel One?

Granules India (GRANULES) share can be brought through the following modes:
  1. Direct investment: You can buy Granules India (GRANULES) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to Granules India (GRANULES) shares.

Is Granules India a Debt free Company?

No, Granules India is not a debt free company.

What is the main business of Granules India?

The main business of Granules India is to produce and sell several high-quality pharmaceutical products, such as Active Pharmaceutical Ingredients (API), Finished doses (FD), and Pharmaceutical Formulation Intermediates (PFI) across India, North America, Europe, and Latin America.

Who are the promoters of Granules India?

Some of the top promoters of Granules India are Krishna Prasad Chigurupati, Chigurupati Uma Devi, Tyche Investments Private Imited, Pragnya Chigurupati, Chigurupati Priyanka, Santhi Sree Ramanavarapu, Suseela Devi Chigurupati, Nikhila Reddy Yedaguri, Harsha Chigurupati, and Venkata Mahesh Krishna Narra.

What are the Subsidiaries that comes under Granules India?

Some of the wholly owned subsidiaries that come under Granules India are Granules USA, Inc., Granules Pharmaceuticals, Inc., Granules Europe Limited, and Granules Life Sciences Private Limited.